These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30576514)

  • 1. The prevalence and clinical significance of microcolonies when tested according to contemporary interpretive breakpoints for fluconazole against Candida species using E-test.
    Hauzer M; Cohen MJ; Polacheck I; Moses A; Korem M
    Med Mycol; 2019 Aug; 57(6):718-723. PubMed ID: 30576514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
    Pfaller MA; Diekema DJ; Sheehan DJ
    Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp.
    Rubio MC; Gil J; De Ocáriz IR; Benito R; Rezusta A
    J Clin Microbiol; 2003 Jun; 41(6):2665-8. PubMed ID: 12791899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of different susceptibility testing methods and media on determination of the relevant fluconazole minimum inhibitory concentrations for heavy trailing Candida isolates with low-high phenotype.
    Alp S; Sancak B; Hascelik G; Arikan S
    Mycoses; 2010 Nov; 53(6):475-80. PubMed ID: 19563491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait.
    Khan Z; Ahmad S; Al-Sweih N; Mokaddas E; Al-Banwan K; Alfouzan W; Al-Obaid I; Al-Obaid K; Asadzadeh M; Jeragh A; Joseph L; Varghese S; Vayalil S; Al-Musallam O
    PLoS One; 2019; 14(5):e0216250. PubMed ID: 31042770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates.
    Marcos-Zambrano LJ; Escribano P; Sánchez-Carrillo C; Bouza E; Guinea J
    Med Mycol; 2016 Oct; 54(7):733-9. PubMed ID: 27161788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the fluconazole trailing effect on the persistence of Candida albicans bloodstream infection when treated with fluconazole.
    Lin SY; Huang HY; Chang LL; Wang YL; Chen TC; Chang K; Tu HP; Lu PL
    Clin Microbiol Infect; 2024 Jul; 30(7):945-950. PubMed ID: 38527614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection].
    Ruhnke M; Schmidt-Westhausen A; Trautmann M
    Mycoses; 1996; 39 Suppl 2():47-50. PubMed ID: 9198745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.
    Rodriguez L; Bustamante B; Huaroto L; Agurto C; Illescas R; Ramirez R; Diaz A; Hidalgo J
    PLoS One; 2017; 12(4):e0175172. PubMed ID: 28419092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibility to fluconazole of clinical interest yeasts: new breakpoints].
    García-Agudo L; García-Martos P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):266-8. PubMed ID: 23303258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy.
    Zhang L; Xiao M; Watts MR; Wang H; Fan X; Kong F; Xu YC
    BMC Infect Dis; 2015 Aug; 15():340. PubMed ID: 26282840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia.
    Iatta R; Caggiano G; Cuna T; Montagna MT
    J Chemother; 2011 Apr; 23(2):92-6. PubMed ID: 21571625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid identification of fluconazole resistance using Chrom agar Candida.
    Verghese SL; Padmaja P; Sutha P; Mathew T; Johni ES
    Indian J Pathol Microbiol; 2001 Jul; 44(3):305-7. PubMed ID: 12024918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole disk diffusion procedure for determining susceptibility of Candida species.
    Barry AL; Brown SD
    J Clin Microbiol; 1996 Sep; 34(9):2154-7. PubMed ID: 8862576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.